Implantica Q2 FY26 operating loss narrows to EUR 4.2 million; net sales rise 66% to EUR 717,000

PUBT · 3d ago
Implantica Q2 FY26 operating loss narrows to EUR 4.2 million; net sales rise 66% to EUR 717,000
  • Implantica posted Q2 net sales up 66% to EUR 717,000; operating loss narrowed to EUR 4.2 million.
  • Loss after tax improved to EUR 3.99 million; basic loss per Class A share narrowed to EUR 0.06.
  • Adjusted gross margin rose 4 percentage points to 94%; cash and cash equivalents totaled EUR 41.7 million.
  • First-half net sales increased 34% to EUR 1.57 million; operating loss narrowed to EUR 8.06 million.
  • FDA PMA approval for RefluxStop secured post-period; RefluxStop sales rose more than 60% year-on-year in Q2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Implantica AG published the original content used to generate this news brief via Cision (Ref. ID: 20260821:BIT:0379:0) on August 21, 2026, and is solely responsible for the information contained therein.